Literature DB >> 8589211

Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells.

L Q Huang1, J A Whitworth, C N Chesterman.   

Abstract

Glucocorticoids reduce prostaglandin synthesis in cultured vascular endothelium, but their effects on other haemostatic functions are unclear. We examined the effects of dexamethasone and cyclosporin A (CSA) on cultured human umbilical vein endothelial cells (HUVEC). One, 10 and 50 micrograms/ml CSA and 1 microgram/ml dexamethasone (Dx) were added to the culture medium for 3 h, 3 days and 6 days and compared with HUVEC cultured in medium and serum alone. After assay of accumulated release of tissue type plasminogen activator (t-PA) and endothelin 1 (ET), cells were stimulated with 1 U/ml of human thrombin for 1 h and medium collected for RIA of 6-keto prostaglandin F1 alpha (6-keto PGF1 alpha), thrombospondin (TSP), von Willebrand factor (vWf) and ELISA of plasminogen activator inhibitor 1 (PAI-1). CSA at 1 microgram/ml modestly reduced release of prostacyclin (PGI2) but had no reproducible effects on other metabolites. CSA at 10 and 50 micrograms/ml inhibited cell growth and thrombin stimulated release of PGI2 in a time- and dose-dependent manner. Inhibition of other endothelial metabolites was also observed at CSA 10 > micrograms/ml. Dexamethasone 1 microgram/ml reduced both cell number and PGI2 release and increased thrombin stimulated release of vWf, TSP and PAI-1 with increases in t-PA and endothelin 1 in the medium. CSA 1 microgram/ml and dexamethasone 1 microgram/ml together were additive in reducing PGI2 release and increasing PAI-1 secretion. These observations suggest a role for endothelial dysfunction in the hypertensive and thrombotic complications observed in steroid treated patients with CSA potentially contributing to such complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589211     DOI: 10.1097/00001721-199507000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  9 in total

Review 1.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Does Chronic Corticosteroid Use Increase Risks of Readmission, Thromboembolism, and Revision After THA?

Authors:  Matthew R Boylan; Dean C Perfetti; Randa K Elmallah; Viktor E Krebs; Carl B Paulino; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2015-11-09       Impact factor: 4.176

3.  A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

Authors:  A O'Donnell; A Padhani; C Hayes; A J Kakkar; M Leach; J M Trigo; M Scurr; F Raynaud; S Phillips; W Aherne; A Hardcastle; P Workman; A Hannah; I Judson
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

4.  Emergent Management of Intracardiac Thrombosis during Liver Transplantation.

Authors:  Caroline Protin; Dmitri Bezinover; Zakiyah Kadry; Thomas Verbeek
Journal:  Case Rep Transplant       Date:  2016-12-14

5.  Methylprednisolone, venous thromboembolism, and association with heparin to 30 days in hospital survival in severe Covid-19 pneumonia.

Authors:  Ronaldo C Go; Themba Nyirenda; Maryam Bojarian; Davood K Hosseini; Mehek Rahim; Kevin Kim; Keith M Rose
Journal:  BMC Pulm Med       Date:  2022-01-06       Impact factor: 3.317

6.  Thromboelastometry in veal calves to detect hemostatic variations caused by low doses of dexamethasone treatment.

Authors:  Antonio Borrelli; Claudio Bellino; Elena Bozzetta; Barbara Bruno; Sara Falco; Cristiana Maurella; Paola Gianella; Marzia Pezzolato; Aurelio Cagnasso; Antonio D'Angelo
Journal:  BMC Vet Res       Date:  2013-03-26       Impact factor: 2.741

7.  Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation.

Authors:  Freeha Arshad; Jelle Adelmeijer; Hans Blokzijl; Aad van den Berg; Robert Porte; Ton Lisman
Journal:  F1000Res       Date:  2014-05-09

8.  Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis.

Authors:  Dmitri Bezinover; Khaled Iskandarani; Vernon Chinchilli; Patrick McQuillan; Fuat Saner; Zakiyah Kadry; Thomas R Riley; Piotr K Janicki
Journal:  BMC Anesthesiol       Date:  2016-05-21       Impact factor: 2.217

9.  Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention.

Authors:  James Yip; David A Bruno; Charlotte Burmeister; Marwan Kazimi; Atsushi Yoshida; Marwan S Abouljoud; Gabriel T Schnickel
Journal:  Transplant Direct       Date:  2016-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.